Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used primarily to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy (nerve pain caused by diabetes), fibromyalgia, chronic musculoskeletal pain (such as low back pain and osteoarthritis), and stress urinary incontinence. It works by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, thereby increasing their levels. This dual action helps regulate mood and reduce pain perception. Duloxetine also increases dopamine levels specifically in the prefrontal cortex via inhibition of norepinephrine transporters but does not directly inhibit dopamine transporters. The drug was originally developed by Eli Lilly[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on duloxetine.